Gastrointestinal Cancer
Conference Coverage
Chemoimmunotherapy, chemoradiotherapy add no survival in pancreatic cancer
Major finding: Median overall survival was 7.9 months for gemcitabine and capecitabine alone, 6.9 months for gemcitabine and capecitabine followed...
News
Benefits of laparoscopic over open colectomy decrease with operative time
Major Finding: The rates of complications and death postoperatively were lower with the laparoscopic approach if the operation lasted 3 hours or...
News
EET and esophagectomy yield similar cancer-free survival
Major finding: No significant differences were seen between the groups with respect to 2-year esophageal cancer-free survival (93.5% and 89.6% in...
News
Cohort study shows link between colonoscopy, overall mortality
Major finding: 18.5% vs. 23% of deceased vs. living patients had a colonoscopy, 17.4% vs. 23.9% had colonoscopy plus FOBT, and 41.4% vs.
News
Urinary test shows promise for pancreatic cancer detection
Major finding: A novel urinary test has 85% sensitivity and 91% specificity for distinguishing pancreatic cancer and chronic pancreatitis.Data...
News
Rates of adjuvant therapy for pancreatic cancer still low
Major finding: The use of surgery alone as first course treatment for stage II pancreatic cancer decreased by nearly 25% at teaching and community...
News
Novel genetic marker predicts pancreatic cancer risk
Major finding: The frequency of the A allele was significantly greater among patients with pancreatic cancer than among controls (odds ratio, 1.57...
Conference Coverage
FIRE-3: Cetuximab/FOLFIRI prolongs metastatic colorectal cancer survival
Major finding: Median overall survival with cetuximab plus FOLFIRI was 28.7 months vs.
News
Onsite cytopathology improves pancreatic biopsy quality
Major finding: Onsite cytopathologists identified significantly more samples as suspicious or malignant than did pathologists who examined samples...